Dr. Chris Mueller is a senior scientist and professor at the Cancer Research Institute at Queen's University in Kingston, Ontario. His research has involved studying epigenetics in different cancers, the relationship between stress and BRCA1, and developing methylation-based liquid biopsies. Chris earned his Ph.D (Microbiology and Immunology) from McGill University. He is involved in all aspects of company growth and has won various grants in advancing mDETECT to clinical validation.

Dr. Irsa (Shoukat) Wiginton is a trained scientist and passionate about translational medicine. She earned her M.Sc. and Ph.D. studying infectious human pathogens at Queen’s University and has successfully completed various certified business development and entrepreneurial training courses. She has a high level understanding of IP strategy, regulatory pathway, commercialization and business model development.

​

​

Keira Frosst  is a dedicated scientist who has been fundamental in the development of the mDETECT tests. Her expertise in NGS-based liquid biopsies is instrumental and she plays a pivotal role in optimizing the assays for commercial sale. She has been the recipient of the Robert J. Wilson Fellowship and is currently on route to participate in the Lab2Market program.

​

​